BioSenic presents successful preclinical data on its ATO medication for controlling key symptoms at the 2024 Systemic Sclerosis World Congress - Seite 2

Understanding the mechanisms of action of arsenic on target cells is essential to determine the best conditions of use and possibly optimal combinations with other drugs. The work of several research teams worldwide has highlighted the autoimmunity-regulating, anti-fibrotic and vascular remodeling properties of arsenic, with potential to treat the lethal lesions in SSc and other autoimmune pathologies.

Dr. Carole Nicco, BioSenic’s CSO and COO, said: "We are pleased to highlight these results, which complement previous findings in another preclinical model of non-genetic but induced-SSc. All our preclinical data, taken together, provide a coherent picture of the significant therapeutic effect we can expect in human patients suffering from severe chronic autoimmune diseases with unmet medical needs."

The results were presented at the 8^th Systemic Sclerosis World Congress last week in Prague, Czech Republic.

About BioSenic

BioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic’s arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).
Following the merger in October 2022, BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO).
BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available at http://www.biosenic.com.

About the main Medsenic/BioSenic technology platform

The ATO platform provides derived active products with immunomodulatory properties and fundamental effects on the activated cells of the immune system. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic, established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT).